Whalesbook
Sai Parenteral's, a pharmaceutical formulations company based in Telangana, has submitted its Draft Red Herring Prospectus (DRHP) to the Securities and Exchange Board of India (SEBI) for its Initial Public Offering (IPO). The issue includes a fresh issuance of shares worth ₹285 crore and an Offer for Sale (OFS) of up to 3.5 million shares. The IPO proceeds are earmarked for significant expansion: ₹110.7 crore for capacity enhancement and manufacturing facility upgrades, ₹18 crore for a new R&D centre, and ₹20 crore for debt repayment. Additionally, ₹33 crore will fund working capital, and ₹36 crore will be invested overseas.
Established in 2013, Sai Parenteral's specializes in research, development, and manufacturing of pharmaceutical formulations, including branded generics and contract development services. Their diverse product portfolio spans various therapeutic areas, and they operate five manufacturing facilities in India, exporting to international markets. Financially, for the fiscal year ended March 31, 2025 (FY25), the company reported revenue of ₹163.1 crore, with Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) rising 24% to ₹39.4 crore, and Profit After Tax (PAT) surging nearly 72% to ₹14.45 crore from the previous fiscal year.
Impact
This development indicates a potential new listing in India's pharmaceutical sector, which could attract investor attention and contribute to market activity. A successful IPO would likely bolster the company's growth trajectory. Rating: 6/10
Difficult Terms:
DRHP (Draft Red Herring Prospectus): A preliminary document filed with the stock market regulator detailing the proposed public offering.
IPO (Initial Public Offering): The first sale of shares by a private company to the public.
OFS (Offer for Sale): Existing shareholders selling their shares during an IPO.
SEBI (Securities and Exchange Board of India): India's capital markets regulator.
QIBs (Qualified Institutional Buyers): Large institutional investors.
NIIs (Non-Institutional Investors): High net-worth individuals and other non-institutional entities.
CDMO (Contract Development and Manufacturing Organization): A service provider for pharmaceutical development and manufacturing.
EBITDA (Earnings Before Interest, Tax, Depreciation, and Amortisation): A measure of operating performance.
PAT (Profit After Tax): The net profit remaining after all expenses and taxes.